Days after President Donald Trump threatened to impose tariffs on foreign drugs, Novartis, an innovative medicines company, has announced plans to invest $23 billion over 5 years in U.S.-based infrastructure, ensuring all key Novartis medicines for U.S. patients will be made in the United States.

This commitment enables Novartis to expand on its current manufacturing, research and technology presence across the country with 10 facilities, including 7 brand new facilities, creating nearly 1,000 new jobs at Novartis and approximately 4,000 additional U.S. jobs. The production capacity will cover both active pharmaceutical ingredients (API) and biologics drug substances, as well as secondary production and packaging.

Over the next 5 years, Novartis will:

• Establish 1 biomedical research innovation hub in San Diego, CA, its second global R&D hub in the U.S.
• Build 4 new manufacturing facilities in soon-to-be-determined states, including 3 that will make biologics drug substances, drug products, device assembly and packaging, and 1 facility that will make chemical drug substances, oral solids dosage forms and packaging
• Build 2 new radioligand therapy (RLT) manufacturing facilities in Florida and Texas
• Expand 3 RLT manufacturing facilities in Indianapolis, IN, Millburn, NJ, and Carlsbad, CA

With these investments, Novartis will have manufacturing capacity in the U.S. for all its core technology platforms, including small molecules and biologics. This new investment will bring internal manufacturing of the company’s siRNA technology to the U.S. for the first time and reflects a commitment to increase U.S. manufacturing across its main therapeutic areas: oncology, immunology, neuroscience, and cardiovascular, renal and metabolic.

With new manufacturing capacity, Novartis will be able to produce 100% of its key medicines end-to-end in the U.S., a significant increase from current levels.

“As a Swiss-based company with a significant presence in the U.S., these investments will enable us to fully bring our supply chain and key technology platforms into the U.S. to support our strong U.S. growth outlook. These investments also reflect the pro-innovation policy and regulatory environment in the U.S. that supports our ability to find the next medical breakthroughs for patients,” said Vas Narasimhan, CEO of Novartis. “We are prepared for shifts in the external environment and fully confident in our 2025 guidance, mid- to long-term sales growth outlook and 2027 core margin guidance of 40%+.”

Over the next 5 years, the total investment in Novartis U.S. operations is expected to be nearly $50 billion, marking a clear demonstration of the company’s focus on the U.S.